Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?

BackgroundSargramostim [recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF)] was approved by US FDA in 1991 to accelerate bone marrow recovery in diverse settings of bone marrow failure and is designated on the list of FDA Essential Medicines, Medical Countermeasures, and...

詳細記述

書誌詳細

主要な著者:	Hillard M. Lazarus, Carolyn E. Ragsdale, Robert Peter Gale, Gary H. Lyman
フォーマット:	Artigo
言語:	Inglês
出版事項:	Frontiers Media S.A. 2021-08-01
シリーズ:	Frontiers in Immunology
主題:	GM-CSF sargramostim immune modulation innate immune response adaptive immune response granulocyte-macrophage colony-stimulating factor
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.706186/full
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!